SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMMULOGIC
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: biowa who wrote (171)5/15/1997 9:45:00 AM
From: David Richardson   of 305
 
BTW, that paper in the Scientist is simply terrible. The woman that wrote it says "When an allergen is inhaled, it travels to the mast cell and binds to the surface IgE antibodies". Open any immunology textbook and you will discover that she is cutting out most of the steps in the process that she is referring to.She says that IMUL is private, which of course we know is false, then she trivializes IMUL's therapy by portraying it as a stronger version of existing therapy. IMUL's technology, if approved by the FDA in a couple of years, will represent a revolutionary advance to existing therapies because it will use molecular biology to stop the allergic reaction from happening in the first place, i.e. down regulate the various events in an allergic reaction ***including the production of IgE***.

Best regards.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News